How Quickly Does Squamous Cell Skin Cancer Spread?

Most cutaneous squamous cell carcinomas (SCCs) grow slowly enough that early detection and removal prevent any spread at all, but the minority that do spread can do so alarmingly fast. In one study of metastatic cases, roughly 38 percent had been noticed for less than six months before spread was detected, and about two and a half percent had been present for less than a month. The speed depends heavily on where on your body the cancer sits, how deep it grows, whether your immune system is compromised, and a handful of other features that clinicians use to sort SCCs into low-risk and high-risk categories. Understanding those categories is more useful than any single timeline, because the gap between the slowest and fastest SCCs is enormous.

How Fast the Tumor Itself Grows

A squamous cell carcinoma typically starts as a firm, scaly bump or a sore that will not heal. Some grow so gradually you barely notice them changing from month to month; others balloon quickly. Researchers studying rapidly growing SCCs found that lesions in that subset averaged only about seven weeks from first appearance to diagnosis, with an average size of roughly 1.3 centimeters, and nearly 20 percent of those fast growers occurred in people with suppressed immune systems.1PubMed. Rapidly growing squamous cell carcinoma

A growth rate of more than 4 millimeters per month appears to be a meaningful cutoff. Tumors exceeding that pace carry a higher risk of spreading to lymph nodes and tend to reach those nodes faster than slower-growing lesions.2Clinical and Experimental Dermatology. Rapid growth rate is associated with poor prognosis in cutaneous squamous cell carcinoma If you notice a spot that seems to be expanding week to week rather than staying put, that pace itself is a warning sign worth bringing to a dermatologist quickly.

Interestingly, a community-based study comparing squamous cell and basal cell carcinoma growth patterns found that basal cell carcinomas steadily increased in size the longer they went untreated, roughly doubling in average diameter over several years. SCCs, by contrast, did not show a consistent pattern of size increasing with time since a patient first noticed them.3PubMed. Basal cell carcinoma and squamous cell carcinoma growth rates and determinants of size in community patients That sounds reassuring until you consider the explanation: SCCs that are going to grow quickly tend to do so early on, and the ones that linger at a small size for years are a different biological animal. The dangerous ones often announce themselves with speed rather than patience.

From Precursor Lesion to Invasive Cancer

Many squamous cell carcinomas begin as actinic keratoses, those rough, sandpapery patches that show up on sun-exposed skin. The progression from an individual actinic keratosis to an invasive SCC is not inevitable. A systematic review found the risk of a single actinic keratosis progressing to invasive or in-situ SCC was about 3 percent at three years and about 4 percent at five years.4PubMed Central. Clinical Characteristics of Actinic Keratosis Associated with the Risk of Progression to Invasive Squamous Cell Carcinoma: A Systematic Review A secondary analysis of a randomized trial found a similar four-year risk of about 3.7 percent for developing SCC after actinic keratosis treatment, with a small number of cancers appearing within the first year.5JAMA Dermatology. Risk of Invasive Cutaneous Squamous Cell Carcinoma After Different Treatments for Actinic Keratosis

Those numbers mean the overwhelming majority of actinic keratoses never become cancer. But if you have many of them, your cumulative risk goes up simply because you have more chances for one to transform. And researchers have found that the tissue surrounding visible actinic keratoses can harbor molecular changes, a concept sometimes called field cancerization, where the whole sun-damaged neighborhood of skin is primed for abnormal growth, not just the one visible spot.6JCI Insight. Multifocal epithelial tumors and field cancerization: stroma as a primary determinant This is why dermatologists often treat broader areas rather than just zapping individual keratoses.

When and How SCCs Spread to Lymph Nodes

The question most people are really asking when they search “how fast does SCC spread” is about metastasis, when cancer cells leave the original tumor and show up somewhere else, usually the nearby lymph nodes first. The overall metastatic rate of cutaneous SCC is low. In a large study with a median follow-up of about six years, roughly 2 to 3 percent of SCCs spread.7PubMed. The incidence of metastasis from cutaneous squamous cell carcinoma and the impact of its risk factors That means for every hundred people diagnosed, somewhere around 97 or 98 will never deal with spread.

But among those whose cancers did metastasize, timing is sobering. A classic study found that about 38 percent of metastases were detected in patients whose tumors had been noticed for less than six months, and roughly 68 percent were detected within the first year.8JAMA Dermatology. Metastases From Squamous Cell Carcinomas of the Skin The same study noted that a small percentage of patients had spread documented in under a month. The takeaway is that metastasis does not only happen in cancers that have been neglected for years. A biologically aggressive SCC can spread early.

The physical route usually starts with enzymes that break down the surrounding tissue architecture, allowing cancer cells to push into deeper layers of skin, enter lymphatic channels, and travel to regional lymph nodes.9PubMed. Matrix metalloproteinases in tumor progression: focus on basal and squamous cell skin cancer From there, spread can continue to distant organs, though this is uncommon in skin SCC compared to SCCs arising inside the body.

What Makes Some SCCs Spread Faster

Not all squamous cell carcinomas are created equal. Several features reliably separate the slow, curable majority from the aggressive minority. These risk factors are what dermatologists and surgeons look at when deciding how closely to follow you after treatment.

Size matters too. A meta-analysis of sentinel lymph node biopsy results found that all primary SCCs with positive lymph nodes were larger than 2 centimeters in diameter. Among those T2 tumors with additional high-risk features, close to 30 percent had positive sentinel nodes, compared with about 7 percent of T2 tumors without those features.14JAMA Dermatology. Staging for Cutaneous Squamous Cell Carcinoma as a Predictor of Sentinel Lymph Node Biopsy Results Those are meaningful differences that help doctors decide who needs more aggressive follow-up or additional treatment.

Immunosuppression Changes the Timeline Dramatically

If you have had an organ transplant or take medications that suppress your immune system for another reason, the rules change. SCCs in transplant recipients are both more common and more aggressive, with a tendency toward multifocal growth and a higher rate of metastasis.15PubMed Central. Squamous cell carcinomas in organ transplant recipients16Frontiers in Medicine. Skin cancer in solid organ transplant recipients: still an open problem

A study tracking organ transplant recipients with aggressive SCC found that the median overall survival was about 28 months, and nearly all of these cancers showed progression within two years of diagnosis. Five-year overall survival in this group was only about 23 percent.17JAMA Dermatology. Aggressive Squamous Cell Carcinoma in Organ Transplant Recipients Those numbers describe a very different disease from the garden-variety SCC in someone with a healthy immune system. One analysis of rapidly growing SCCs found that about one in five occurred in people who were immunosuppressed.1PubMed. Rapidly growing squamous cell carcinoma

Transplant recipients develop SCCs at many times the rate of the general population, and those cancers arrive earlier, recur more often, and spread more readily. If you are in this group, your dermatologist should be seeing you at least once or twice a year, and any new or changing skin lesion warrants prompt attention rather than a wait-and-see approach.

Recurrence After Treatment

Even after a squamous cell carcinoma has been completely removed, high-risk tumors can come back. A study of advanced head and neck SCCs found that about 31 percent of patients experienced recurrence, split roughly evenly between local recurrence (cancer returning at the original site), regional recurrence (showing up in nearby lymph nodes), and distant recurrence (spreading to organs). The majority of regional and distant recurrences happened within the first year after surgery.18PubMed. Recurrence Patterns of Advanced Cutaneous Squamous Cell Carcinoma of the Head and Neck

This first-year concentration has practical implications. If your SCC was classified as high-risk, expect your doctor to schedule frequent follow-up visits during the first one to two years. After that window, the risk of recurrence drops significantly, though it never reaches zero. Low-risk SCCs, by contrast, have recurrence rates in the low single digits and rarely need intensive surveillance.

Does Delaying Treatment Make Things Worse?

Intuitively you would expect that waiting longer to see a doctor means a worse outcome, and there is some evidence for that, though the relationship is not perfectly straightforward. A study looking at patient delay and tumor characteristics found that longer delays correlated with larger tumor size at diagnosis.19PubMed Central. Prognostic Factors in Cutaneous Squamous Cell Carcinoma: Is Patient Delay in Hospital Visit a Predictor of Survival? However, the same study found that the tumors in patients who waited longer tended to be the slower-growing type. The biologically aggressive SCCs that grow quickly tend to force a visit sooner because they are alarming to look at, while the quiet, slow growers are the ones people put off.

The practical message is nuanced: a slowly growing SCC that you have had for a while is not necessarily safe just because it has been slow. And a fast-growing one is not necessarily a death sentence just because it appeared seemingly overnight. Speed of growth is one risk factor among several. What matters most is getting any suspicious lesion evaluated, regardless of how long it has been there or how fast it seems to be changing.

Staging and Predicting Individual Risk

Clinicians use staging systems to estimate how likely a given SCC is to spread. The two most widely used are the American Joint Committee on Cancer (AJCC) system and the Brigham and Women’s Hospital (BWH) system. Both consider tumor size, depth, and the presence of high-risk features like perineural invasion or poor differentiation. Researchers are working on more refined models that combine multiple clinical and pathological variables to estimate an individual patient’s absolute metastatic risk, rather than sorting everyone into broad categories.20Cancer Research. Abstract 3463: Beyond staging systems in cutaneous squamous cell carcinoma: Validation of two thresholds for a model-estimated metastatic risk

This is still an area where the science is evolving. Current staging systems work reasonably well at the extremes: a tiny, well-differentiated SCC on the arm in a healthy person is almost certainly going to be cured with simple excision, and a thick, poorly differentiated SCC on the ear of a transplant recipient warrants aggressive treatment. The tricky cases are the ones in the middle, where the tumor has one or two high-risk features but is not obviously dangerous. Better predictive models should eventually help doctors tailor follow-up schedules and decide who benefits from sentinel lymph node biopsy or additional imaging.

The Genetics Behind Aggressive Behavior

At the molecular level, aggressive SCCs tend to accumulate mutations in specific genes. Researchers sequencing the DNA of aggressive cutaneous SCCs identified more than 20 candidate driver genes, including TP53 (a well-known tumor suppressor that is mutated in many cancers), CDKN2A, and NOTCH1. Mutations in a gene called KMT2C were associated with worse outcomes and a higher rate of bone invasion.21Clinical Cancer Research. Mutational Landscape of Aggressive Cutaneous Squamous Cell Carcinoma

This kind of molecular profiling is not yet routine in clinical practice for most skin SCCs, but it is shaping how researchers think about treatment targets. The very high number of mutations in SCCs, largely driven by ultraviolet radiation damage, actually creates an opportunity: tumors with lots of mutations tend to produce many abnormal proteins on their surfaces, making them more visible to the immune system. That feature is why immunotherapy has shown real promise for advanced SCC.

Treatment Options When SCC Has Spread

For the majority of SCCs caught early, treatment is surgical and highly effective. Mohs micrographic surgery, where the surgeon removes tissue in thin layers and examines each one under a microscope during the procedure, offers cure rates above 95 percent for primary tumors. Standard excision with adequate margins is also effective for most cases.

When SCC has advanced locally or metastasized to lymph nodes or beyond, treatment enters different territory. The arrival of immune checkpoint inhibitors has been a genuine shift. Cemiplimab, a drug that blocks the PD-1 protein on immune cells, produced responses in about half of patients with metastatic SCC in clinical trials.22PubMed. PD-1 Blockade with Cemiplimab in Advanced Cutaneous Squamous-Cell Carcinoma Extended dosing schedules have shown similar activity with durable responses, meaning the cancer stayed controlled for extended periods in many responders.23PubMed Central. High response rate with extended dosing of cemiplimab in advanced cutaneous squamous cell carcinoma

Before immunotherapy, the options for metastatic cutaneous SCC were limited mostly to traditional chemotherapy and radiation, which could shrink tumors but rarely produced lasting control. The fact that about half of advanced SCC patients now respond to PD-1 blockade represents a meaningful improvement, though it also means roughly half do not respond, and the search for better combinations and second-line options continues. For transplant recipients, immunotherapy presents a particular dilemma, since the drugs work by unleashing the immune system, which is exactly what anti-rejection medications are designed to suppress. Managing that tension requires close coordination between oncologists and transplant teams.

Practical Signals Worth Knowing

If you are keeping an eye on a spot and wondering when to worry, a few practical signals are worth tracking. A sore that bleeds, crusts over, and then reopens repeatedly is the classic SCC presentation. Rapid growth, meaning visible expansion over weeks rather than months, pushes the lesion into higher-risk territory. Tenderness, numbness, or tingling near the lesion could suggest the tumor is involving nerves. And location matters: anything on the ear, lip, or near the eye deserves faster evaluation than something on the forearm or back.

People often compare SCC to melanoma and assume it is always the “less dangerous” skin cancer. That framing is broadly true for the typical case but dangerously misleading for the atypical one. A thick, poorly differentiated SCC on the ear of someone who is immunosuppressed is a serious cancer with real metastatic potential and mortality risk. Treating every SCC as trivial just because most of them are curable is one of the more common misconceptions in skin cancer awareness. The most useful mental model is that squamous cell carcinoma exists on a spectrum, and the features described throughout this article are what determine where on that spectrum a given tumor falls.